Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or VSports app下载. mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely V体育官网. .

Clinical Trial
. 2006 Mar 15;12(6):1750-9.
doi: 10.1158/1078-0432.CCR-05-2000.

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group

Kaci L Osenga  1 , Jacquelyn A Hank, Mark R Albertini, Jacek Gan, Adam G Sternberg, Jens Eickhoff, Robert C Seeger, Katherine K Matthay, C Patrick Reynolds, Clare Twist, Mark Krailo, Peter C Adamson, Ralph A Reisfeld, Stephen D Gillies, Paul M Sondel; Children's Oncology Group
Affiliations
Clinical Trial

"V体育官网" A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group

Kaci L Osenga et al. Clin Cancer Res. .

Abstract (VSports最新版本)

Purpose: Evaluate the clinical safety, toxicity, immune activation/modulation, and maximal tolerated dose of hu14 VSports手机版. 18-IL2 (EMD 273063) in pediatric patients with recurrent/refractory neuroblastoma and other GD2-positive solid tumors. .

Experimental design: Twenty-seven pediatric patients with recurrent/refractory neuroblastoma and one with melanoma were treated with a humanized anti-GD2 monoclonal antibody linked to human interleukin 2 (IL-2). Cohorts of patients received hu14 V体育安卓版. 18-IL2, administered i. v. over 4 hours for three consecutive days, at varying doses. Patients with stable disease, partial, or complete responses were eligible to receive up to three additional courses of therapy. .

Results: Most of the clinical toxicities were anticipated and similar to those reported with IL-2 and anti-GD2 monoclonal antibody therapy and to those noted in the initial phase I study of hu14. 18-IL2 in adults with metastatic melanoma. The maximal tolerated dose was determined to be 12 mg/m2/d, with agent-related dose-limiting toxicities of hypotension, allergic reaction, blurred vision, neutropenia, thrombocytopenia, and leukopenia. Three patients developed dose-limiting toxicity during course 1; seven patients in courses 2 to 4. Two patients required dopamine for hypotension V体育ios版. There were no treatment-related deaths, and all toxicity was reversible. Treatment with hu14. 18-IL2 led to immune activation/modulation as evidenced by elevated serum levels of soluble IL-2 receptor alpha (sIL2Ralpha) and lymphocytosis. The median half-life of hu14. 18-IL2 was 3. 1 hours. There were no measurable complete or partial responses to hu14. 18-IL2 in this study; however, three patients did show evidence of antitumor activity. .

Conclusion: Hu14. 18-IL2 (EMD 273063) can be administered safely with reversible toxicities in pediatric patients at doses that induce immune activation. A phase II clinical trial of hu14 VSports最新版本. 18-IL2, administered at a dose of 12 mg/m2/d x 3 days repeated every 28 days, will be done in pediatric patients with recurrent/refractory neuroblastoma. .

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Lymphocyte counts. Columns, mean lymphocyte counts of all 28 patients in all four courses of immunocytokine therapy based on blood samples before treatment on the indicated days; bars, SE.
Fig. 2
Fig. 2
Correlation of boost in lymphocyte counts on day 8 (lymphocyte count on day 8 lymphocyte count on day 0) of course 1 and dose level. The boost in lymphocyte count on day 8 shows a positive correlation with the dose of immunocytokine given (P = 0.002).
Fig. 3
Fig. 3
Correlation of peak concentration of hu14.18-IL2 detected on day 1 and on day 3 with the boost in lymphocyte count detected on day 8 (value for day 8 value for day 0) for course 1. Spearman’s rank correlation analysis was done to correlate a change from baseline to day 8 lymphocyte counts versus peak concentration of hu14.18-IL2 on day 1 or 3. There is a significant positive correlation between these variables with P = 0.001 for hu14.18-IL2 levels on day 1 (A) and P = 0.0006 for the hu14.18-IL2 level on day 3 (B).
Fig. 4
Fig. 4
sIL2R levels on various days of each course of treatment. Columns, average serum sIL2R levels obtained for serum samples from all patients for each of the designated courses; bars, SE.
Fig. 5
Fig. 5
Correlation between sIL2 receptor levels and peak concentration of immunocytokine. AUC of serum sIL2R levels measured from days 0 to 22, during course 1 was computed using the trapezoid rule for each subject. Spearman’s rank correlation coefficient was calculated between sIL2r AUC and peak concentration of immunocytokine for day 1 of course 1. There is a positive correlation between these two variables (P = 0.009). Therefore, a higher sIL2r AUC is associated with higher peak concentrations of hu14.18-IL2.
See this image and copyright information in PMC

References

    1. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380–4. - "VSports手机版" PubMed
    1. Mule JJ, Yang JC, Lafreniere R, Shu SY, Rosenberg SA. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high dose recombinant interleukin-2. J Immunol. 1987;139:285–94. - VSports手机版 - PubMed
    1. Albertini MR, Sondel PM. Tumor immunology and immunotherapy. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, editors. Clinical oncology. 2. London: Churchill Livingstone; 2000. pp. 214–41.
    1. Colucci F, Caligiuri MA, Di Santo JP. What does it take to make a natural killer? Nat Rev Immunol. 2003;3:413–25. - PubMed
    1. Cheung NK, Sondel PM. Neuroblastoma: immunology and immunotherapy. In: Cohn S, Cheung NK, editors. Neuroblastoma. New York: Springer Press; 2005. pp. 223–42.

Publication types

V体育ios版 - MeSH terms

V体育安卓版 - Substances